

CITATION REPORT

List of articles citing

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

DOI: 10.7326/0003-4819-110-5-353

Annals of Internal Medicine, 1989, 110, 353-6.

Source: <https://exaly.com/paper-pdf/20314504/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
415	Cyclosporine treatment for inflammatory bowel disease: a step backward or a leap forward?. 1989 , 321, 894-6		13
414	Newer pharmacologic agents for the therapy of inflammatory bowel disease. 1990 , 74, 133-53		8
413	Therapeutic progress--review XXXVII. Methotrexate--an immunomodulator with expanding indications. 1990 , 15, 89-95		3
412	Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. 1990 , 19, 337-52		27
411	Clinical pharmacology and therapeutics. 1990 , 66, 166-85		4
410	Inflammatory bowel disease revisited: newer drugs. 1990 , 175, 97-106		12
409	Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. 1990 , 336, 16-9		263
408	Methotrexate: anti-inflammatory or antiproliferative?. 1990 , 22, 523-4		13
407	Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. 1990 , 117, 653-9		77
406	Inflammatory bowel disease. Part II: Clinical and therapeutic aspects. 1991 , 37, 669-746		16
405	6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. 1991 , 66, 480-4		21
404	Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. 1991 , 24, 973-8		86
403	Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. 1991 , 6, 192-219		61
402	The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. 1991 , 101, 84-9		139
401	Immunosuppressive therapy in autoimmune disease--a review. 1991 , 160, 199-205		4
400	Inflammatory bowel disease (2). 1991 , 325, 1008-16		276
399	New forms of treatment for inflammatory bowel disease. 1992 , 33, 1301-2		7

- 398 Medical therapy in Crohn's disease. **1992**, 92, 169-73, 177-8, 183 passim 2
- 397 Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. **1992**, 27, 968-72 26
- 396 Drug therapy of ulcerative colitis. **1992**, 34, 189-98 47
- 395 New therapeutic agents in the treatment of inflammatory bowel disease. **1992**, 93, 199-208 25
- 394 Methotrexate transport in the human intestine. Evidence for heterogeneity. **1992**, 43, 2377-83 22
- 393 Drug therapy for inflammatory bowel disease: Part II. **1992**, 164, 178-85 9
- 392 Three cases of malignant neoplasm, pneumonitis, and pancytopenia during treatment with low-dose methotrexate. **1992**, 70, 951-5 13
- 391 Medical management of severe inflammatory disease of the rectum and distal colon: non-nutritional aspects. **1992**, 6, 1-26 4
- 390 New developments in the pharmacotherapy of inflammatory bowel disease. **1992**, 14, 275-86 5
- 389 Low-dose oral methotrexate in refractory inflammatory bowel disease. **1993**, 38, 1851-6 95
- 388 Better effect of methotrexate on C-reactive protein during daily compared to weekly treatment in rheumatoid arthritis. **1993**, 12, 210-3 4
- 387 Current management of inflammatory bowel disease. **1993**, 8, 70-83 10
- 386 Medical therapy of ulcerative colitis. **1993**, 342, 412-7 52
- 385 Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. **1993**, 104, 31-7 76
- 384 Immune modulating therapies for idiopathic inflammatory bowel diseases. **1994**, 25, 171-234 9
- 383 Immunomodulator therapy in inflammatory bowel disease. **1994**, 39, 1885-92 38
- 382 Efficacy of cyclosporine in treatment of fistula of Crohn's disease. **1994**, 39, 374-80 221
- 381 High-dose methotrexate treatment and liver function in patients with osteosarcoma. **1994**, 236, 209-14 7

380	Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. 1994 , 31, 620-5	53
379	Treatment of inflammatory bowel disease from now to the millennium. 1994 , 8, 351-79	3
378	[Treatment of Crohn disease in adults]. 1994 , 15, 676-89	
377	Inflammatory Bowel Disease. 1994 , 2, 134-160	5
376	Mucosal interleukin-6 secretion in ulcerative colitis. Effects of anti-inflammatory drugs and T-cell stimulation. 1994 , 29, 722-8	14
375	The role of methotrexate in the management of steroid-dependent asthma. 1994 , 105, 117-21	45
374	Medical therapy of inflammatory bowel disease. 1994 , 78, 1413-26	18
373	Immunopathogenesis of chronic inflammatory bowel disease. 1994 , 83, 18-21	8
372	Medical Therapy of Ulcerative Proctitis and Proctosigmoiditis, Including Refractory Disease. 1995 , 1, 207-219	3
371	The effect of immunosuppressive agents on monocyte generation and cytokine expression. 1995 , 1, 266-75	4
370	¹¹¹ In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment?. 1995 , 9, 149-52	0
369	The management of ulcerative colitis. 1995 , 46, 497-505	15
368	Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. 1995 , 332, 292-7	782
367	European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. 1995 , 109, 774-82	130
366	An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. 1995 , 109, 1808-17	132
365	Methotrexate for refractory Crohn's disease: preliminary answers to definitive questions. 1996 , 71, 104-5	5
364	Ulcerative colitis in children. 1996 , 43, 235-54	21
363	Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. 1996 , 71, 69-80	69

362	Newer treatments for inflammatory bowel disease. 1996 , 23, 577-608	10
361	123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. 1996 , 23, 685-92	49
360	[Use of methotrexate in spondylarthropathies. Review of the literature]. 1996 , 17, 333-9	3
359	In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. 1996 , 23, 1388-99	31
358	Inflammatory Bowel Disease: The Asthma of the Intestine?. 1996 , 2, 122-132	2
357	Chapter 6 Glycoproteins in inflammatory bowel disease. 1996 , 30, 291-298	4
356	Inflammatory bowel disease: The asthma of the intestine?. 1996 , 2, 122-132	2
355	Review article: the medical management of Crohn's disease. 1996 , 10, 1-22	34
354	Review article: refractory distal colitis -- explanations and options. 1996 , 10, 39-48	17
353	Methotrexate for psoriasis. 1996 , 21, 399-408	59
352	Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. 1996 , 39, 846-51	273
351	Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease?. 1997 , 32, 933-41	21
350	Methotrexate use in miscellaneous inflammatory diseases. 1997 , 23, 855-82	9
349	Inflammatory bowel disease in the elderly. Practical treatment guidelines. 1997 , 10, 199-208	18
348	Autoimmune Reactivity in Inflammatory Bowel Disease. 1997 , 17, 465-481	5
347	Safety of corticosteroids and immunosuppressive agents in ulcerative colitis. 1997 , 11, 111-28	2
346	Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. 1997 , 25, 129-157	220
345	The absorption of low-dose methotrexate in patients with inflammatory bowel disease. 1997 , 11, 569-73	29

344	Medical therapy of active Crohn's disease. 1998 , 12, 73-92	9
343	Consensus conference on the evaluation of drugs to treat children with inflammatory bowel disease. Philadelphia, Pennsylvania, USA. October 18-19, 1997. 1998 , 4, 101-31	2
342	Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Management of fistula disease. 1998 , 4, 302-7	10
341	Methotrexate in patients with Crohn's disease after 6-mercaptopurine. 1998 , 132, 830-5	73
340	Inflammatory bowel disease: short- and long-term treatments. 1998 , 44, 144-72	3
339	Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. 1998 , 33, 637-43	41
338	A practical guide to the management of distal ulcerative colitis. 1998 , 55, 519-42	38
337	Sarcoidosis presenting as granulomatous colitis. 1998 , 93, 1949-51	19
336	Methotrexate treatment for Crohn's disease. 1998 , 4, 120-1	5
335	Summary of the workshop on methotrexate pharmacology. 1998 , 4, 123-4; discussion 124-5	
334	Methotrexate therapy for pediatric patients with inflammatory bowel disease. 1998 , 4, 121-3	4
333	Ulcerative colitis in young adults. Complexities of diagnosis and management. 1998 , 103, 45-9, 53-6, 59	5
332	[Follow-up study of fistula in Crohn's disease]. 1999 , 36, 207-9	0
331	A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. 1999 , 13, 1597-604	66
330	Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. 1999 , 65, 29-39	43
329	Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. 1999 , 44, 424-30	71
328	Nonobstructing Crohn's Disease. 1999 , 2, 134-143	
327	Inflammatory bowel disease. 1999 , 26, 141-70	14

326	Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. 1999 , 116, 1029-34	679
325	Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. 1999 , 50, 667-71	188
324	Medical therapy for inflammatory bowel disease. 1999 , 28, 297-321	66
323	Medical therapy of specific clinical presentations. 1999 , 28, 353-70, viii	7
322	Methotrexate in refractory Crohn's disease. 1999 , 5, 11-5	32
321	How to do without steroids in inflammatory bowel disease. 2000 , 6, 48-57; discussion 58	67
320	Clinical Outcome and Pharmacokinetics After Addition of Low-Dose Cyclosporine to Methotrexate: A Case Study of Five Patients with Treatment-Resistant Inflammatory Bowel Disease. 2000 , 6, 286-289	7
319	Update in medical treatment of Crohn's disease. 2000 , 31, 282-91	12
318	Methotrexate use in rheumatoid arthritis. A Clinician's perspective. 2000 , 47, 259-71	46
317	Long-term treatment of Crohn's disease with methotrexate, or, why's a nice drug like you still a wannabe in the treatment of inflammatory bowel disease?. 2000 , 95, 1619-20	1
316	Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. 2000 , 95, 1201-7	60
315	A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. 2000 , 342, 1627-32	593
314	Computational predictions of binding affinities to dihydrofolate reductase: synthesis and biological evaluation of methotrexate analogues. 2000 , 43, 3852-61	32
313	Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. 2000 , 1, 27-39	33
312	Methotrexate in Crohn's disease: long-term efficacy and toxicity. 2000 , 95, 1730-4	38
311	Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. 2000 , 95, 3150-6	137
310	Tratamiento médico de la enfermedad de crohn. 2000 , 8, 279-283	
309	Treatment of fistulizing Crohn's disease. 2000 , 119, 1132-47	78

308	Comparative tolerability of treatments for inflammatory bowel disease. 2000 , 23, 429-48	135
307	Pharmacokinetic considerations in the treatment of inflammatory bowel disease. 2001 , 40, 723-51	97
306	Medical therapy for Crohn's disease: the state of the art. 2001 , 81, 71-101, viii	23
305	Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. 2001 , 33, 548-53	29
304	Efficacy of parenteral methotrexate in refractory Crohn's disease. 2001 , 15, 35-44	58
303	Methotrexate: a useful alternative in Crohn's disease?. 2001 , 49, 9-10	5
302	Methotrexate in Crohn's disease. 2001 , 48, 790-1	23
301	Methotrexate for induction of remission in refractory Crohn's disease. 2003 , CD003459	11
300	Ulcerative colitis in children: medical management. 2002 , 4, 807-15	5
299	Autologous hematopoietic stem cell transplantation for Crohn's disease. 2002 , 1, 244-9	7
298	Medical treatment of Crohn's disease. 2002 , 31, 167-84, x	9
297	Recent developments in inflammatory bowel disease. 2002 , 86, 1497-523	13
296	Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. 2002 , 22, 613-20	9
295	Review article: medical treatment of active Crohn's disease. 2002 , 16 Suppl 4, 35-9	8
294	Review article: monitoring for drug side-effects in inflammatory bowel disease. 2002 , 16, 647-62	58
293	The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. 2002 , 16, 693-7	92
292	Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. 2002 , 16, 1751-9	98
291	Review article: medical treatment of moderate to severe Crohn's disease. 2003 , 17 Suppl 2, 23-30	11

290	Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. 2003 , 18, 57-63	64
289	Fistula response to methotrexate in Crohn's disease: a case series. 2003 , 18, 1003-8	69
288	Hematopoietic stem cell transplantation for severe Crohn's disease. 2003 , 32 Suppl 1, S57-9	32
287	Treatment of inflammatory bowel disease in childhood: best available evidence. 2003 , 9, 34-58	88
286	Considerations in the management of steroid-dependent Crohn's disease. 2003 , 125, 906-10	11
285	Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. 2003 , 42, 139-51	100
284	Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. 2003 , 35, 619-27	103
283	Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model. 2003 , 46, 3455-62	19
282	Low dose methotrexate in inflammatory bowel disease: current status and future directions. 2003 , 98, 530-7	51
281	Peptide targeted imaging of cancer. 2003 , 18, 675-87	18
280	Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. 2003 , 52, 1286-90	74
279	Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage. 2003 , 36, 238-41	40
278	Methotrexate-induced pulmonary injury: serial CT findings. 2003 , 18, 231-6	28
277	Methotrexate-induced esophagitis in a child with Crohn disease. 2003 , 37, 514-6	6
276	Medical treatment of ulcerative colitis. 2004 , 17, 7-19	37
275	Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. 2004 , 39, 395-403	122
274	Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. 2004 , 13, 426-34	50
273	Mucosal healing in pediatric Crohn's disease: the goal of medical treatment. 2004 , 10, 479-80	32

272	[Immunosuppressants and MICI]. 2004 , 28, 685-95	
271	[Treatment of extended ulcerative colitis (severe colitis excluded)]. 2004 , 28, 974-83	4
270	[Induction and maintenance of remission in ulcerative colitis]. 2004 , 28, 992-1004	3
269	Ulcerative colitis: conservative management and long-term effects. 2004 , 389, 350-3	5
268	Medical approaches and future options in chronic active ulcerative colitis. 2004 , 19, 297-307	7
267	Perianal Crohn's disease. 2004 , 91, 801-14	129
266	Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. 2004 , 43, 1469-77	72
265	Methotrexate for induction of remission in refractory Crohn's disease. 2005 , CD003459	53
264	Management of refractory inflammatory bowel disease. 2004 , 33, 319-34, x	3
263	Methotrexate in inflammatory bowel disease. 2004 , 33, 407-20, xi	20
262	Efficacy of conventional immunosuppressive drugs in IBD. 2004 , 36, 766-80	12
261	Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. 2004 , 99, 2235-41	188
260	The role and importance of endoscopic mucosal healing in Crohn's disease. 2004 , 6, 138-143	4
259	Endoscopic scoring system for Crohn's disease: viva the evolution!. 2004 , 60, 590-1	2
258	Experience with the use of low-dose methotrexate for inflammatory bowel disease. 2004 , 16, 921-6	50
257	Low-dose methotrexate in ulcerative colitis: still a matter of debate. 2004 , 16, 1071-2; author reply 1072	
256	The bioavailability of oral methotrexate in children with inflammatory bowel disease. 2005 , 40, 445-9	21
255	Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand. 2005 , 39, 751-6	13

254	Oral methotrexate in ulcerative colitis. 2005 , 21, 385-9	64
253	Review article: monitoring of immunomodulators in inflammatory bowel disease. 2005 , 21, 307-19	55
252	Review article: practical management of inflammatory bowel disease patients taking immunomodulators. 2005 , 22, 1-16	88
251	Normal homocysteine levels in a population of children with inflammatory bowel disease. 2005 , 11, 620-1	
250	Medical management of ulcerative colitis. 2003 , 605-629	
249	Advances in the Medical Treatment of Crohn's Disease. 2005 , 59-92	1
248	Medical therapy for Crohn's disease. 2003 , 659-680	
247	Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. 2003 , 495-521	1
246	Chronisch entzündliche Darmerkrankungen. 2005 , 248-287	
245	Synergy between immunosuppressive therapy and enteral nutrition in the management of childhood Crohn's disease. 2005 , 29, S160-3; discussion S163-5, S184-8	3
244	Severe and steroid-resistant Crohn's disease. 2005 , 71, 19-25	14
243	Maintenance of remission in Crohn's disease. 2005 , 71, 41-8	12
242	Vascular endothelial growth factor expression and microvessel parameters of colonic mucosa correlate with sensitivity to steroid in patients with ulcerative colitis. 2005 , 40, 188-93	6
241	The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. 2005 , 114, 154-63	179
240	Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. 2005 , 128, 552-63	269
239	Tratamiento de la enfermedad de Crohn corticodependiente y corticorrefractaria. 2006 , 13, 150-158	
238	Case study: longitudinal treatment of adolescents with depression and inflammatory bowel disease. 2006 , 45, 396-400	30
237	Medical therapy for refractory pediatric Crohn's disease. 2006 , 4, 1199-213	7

236	Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question. 2006 , 63, 493-6	1
235	Mucosal healing in Crohn's disease: what you see is what you get?. 2006 , 63, 443-4	6
234	Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. 2006 , 24, 651-60	48
233	Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. 2007 , 25, 3-12	80
232	Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. 2006 , 12, 311-27	43
231	Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. 2006 , 12, 1053-7	60
230	Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. 2006 , 14, 8608-21	152
229	Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. 2007 , 56, 453-5	214
228	Are we ready for top-down therapy for inflammatory bowel diseases: pro. 2007 , 1, 243-8	4
227	Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. 2007 , 102, 2804-12; quiz 2803, 2813	85
226	Severe and steroid-resistant Crohn's disease. 2007 , 76, 99-108	4
225	Maintenance of medically induced remission of Crohn's disease. 2007 , 76, 116-29	3
224	Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. 2007 , 29, 619-25	36
223	Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. 2007 , 44, 414-22	100
222	Role of methotrexate in the management of Crohn disease. 2007 , 44, 427-30	27
221	Methotrexate for induction of remission in ulcerative colitis. 2007 , CD006618	10
220	Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. 2007 , 46, 1290-1298	132
219	Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. 2007 , 39, 438-44	35

218	Review article: the pharmacological implications of leucocyte-endothelial cell interactions in Crohn's disease. 1991 , 5, 1-14		15
217	Review article: immunosuppressive therapy for inflammatory bowel disease. 1993 , 7, 117-23		14
216	Rolling review: inflammatory bowel disease. 1993 , 7, 567-79		17
215	Review article: the management of steroid dependency in ulcerative colitis. 2007 , 26, 779-94		43
214	Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. 2007 , 26, 987-1003		78
213	Combination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid-based formula induced remission in a patient with steroid-dependent, chronically active ulcerative colitis. 2007 , 22, 833-9		11
212	Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. 2008 , 14, 756-62		18
211	Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. 2008 , 41, 571-7		27
210	A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. 2008 , 23, 954-8		35
209	Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?. 2008 , 32, 153-7		10
208	European evidence-based Consensus on the management of ulcerative colitis: Current management. <i>Journal of Crohn's and Colitis</i> , 2008 , 2, 24-62	1.5	371
207	Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. 2008 , 42, 395-9		34
206	Treatment of inflammatory bowel disease: a review of medical therapy. <i>World Journal of Gastroenterology</i> , 2008 , 14, 354-77	5.6	163
205	Ulcerative colitis: current treatment strategies and future prospects. <i>Therapeutic Advances in Gastroenterology</i> , 2009 , 2, 99-108	4.7	39
204	Profile of depression in adolescents with inflammatory bowel disease: implications for treatment. 2009 , 15, 69-74		32
203	Therapeutic strategies for the management of ulcerative colitis. 2009 , 15, 935-50		56
202	Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. 2009 , 15, 1295-301		499
201	Successful implementation of a nurse-led teaching programme to independently administer subcutaneous methotrexate in the community setting to children with Crohn's disease. 2009 , 29, 90-6		7

200	Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. 2009 , 30, 614-20	73
199	Methotrexate for maintenance of remission in ulcerative colitis. 2009 , CD007560	9
198	First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. 2009 , 15, 505-11	19
197	Inflammatory bowel disease. 2009 , 108, e1-10	28
196	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2009 , 38, 577-94	19
195	Pulmonary Complications of Antirheumatic Therapies. 2009 , 16, 315-322	2
194	Systematic review on drug and diet-induced endoscopic remission in Crohn's disease. 2009 , 21, 491-503	6
193	Impact of autonomic dysfunction on inflammatory bowel disease. 2010 , 44, 272-9	21
192	Methotrexate-induced pneumonitis in Crohn's disease. Case report and review of the literature. 2010 , 5, 312-9	13
191	Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease. 2010 , 55, 2309-15	14
190	Does methotrexate induce mucosal healing in Crohn's disease?. 2010 , 16, 377-8	17
189	Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. 2010 , 16, 494-500	17
188	Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. 2010 , 16, 1195-202	15
187	Efficacy of methotrexate in ulcerative colitis: failure or promise. 2010 , 16, 1421-30	26
186	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. 2010 , 16 Suppl 1, S1-11	14
185	Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. 2010 , 32, 313-23	12
184	Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. 2010 , 32, 1017-22	12
183	Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. 2010 , 116, 6123-32	128

182	Efficacy and safety of drugs for ulcerative colitis. 2010 , 9, 573-92		24
181	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2010 , 94, 1-18		26
180	The potential for disease modification in Crohn's disease. 2010 , 7, 79-85		72
179	Clinical implications of mucosal healing for the management of IBD. 2010 , 7, 15-29		347
178	Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. 2010 , 105, 1620-6		43
177	Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 397-401	1.5	21
176	The safety and tolerability of methotrexate for treating patients with Crohn's disease. 2011 , 45, 599-601		12
175	Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. 2011 , 52, 38-42		47
174	Review article: explaining risks of inflammatory bowel disease therapy to patients. 2011 , 33, 23-32		80
173	Review article: the role of non-biological drugs in refractory inflammatory bowel disease. 2011 , 33, 417-27		24
172	Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. 2011 , 33, 714-21		62
171	Practical application of anti-TNF therapy for luminal Crohn's disease. 2011 , 17, 2366-91		15
170	Medication Repurposing: New Uses for Old Drugs. 2011 , 27, 132-140		5
169	Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial. 2011 , 106, 1527-43		18
168	Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. 2012 , 97, 2134-42		64
167	Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. 2012 , 24, 1086-91		19
166	Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. 2012 , 13, 472-7		6
165	Using the Children's Depression Inventory in youth with inflammatory bowel disease: support for a physical illness-related factor. 2012 , 53, 1194-9		22

164	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 116-31	1.5	13
163	Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 492-502	1.5	27
162	Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick?. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 621-5	1.5	6
161	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 991-1030	1.5	715
160	The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. 2012 , 44, 123-7		44
159	Methotrexate for induction of remission in refractory Crohn's disease. 2012 , 12, CD003459		32
158	Methotrexate: underused and ignored?. 2012 , 30 Suppl 3, 112-8		15
157	Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. 2012 , 19, 329-37		29
156	Surgical treatment of ulcerative colitis in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2012 , 18, 1861-70	5.6	32
155	[Guidelines for the management of ulcerative colitis]. 2012 , 59, 118-40		25
154	Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. 2012 , 18, 359-67		49
153	Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. 2012 , 35, 284-91		16
152	Mucosal healing in Crohn's disease: a systematic review. 2013 , 19, 429-44		106
151	Recent advances using immunomodulators for inflammatory bowel disease. 2013 , 53, 575-88		30
150	Definition and evaluation of mucosal healing in clinical practice. 2013 , 45, 969-77		87
149	Rola terapii biologicznej w podtrzymaniu remisji u dzieci z chorobami Leśniowskiego i Crohna. 2013 , 88, 131-137		1
148	The role of ultrasound in the evaluation of inflammatory bowel disease. 2013 , 48, 224-33		19
147	Efficacy, safety and tolerability of vedolizumab in patients with inflammatory bowel disease: the ENTRANCE study. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 636-43	1.5	45

146	Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. 2013 , 45, 978-85		42
145	Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. 2013 , 37, 340-5		18
144	Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease. 2013 , 11, 667-72		26
143	Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. 2013 , 19, 96-109		33
142	Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System. 2013 , 19, 1379-83		19
141	Histological healing in inflammatory bowel disease: a still unfulfilled promise. <i>World Journal of Gastroenterology</i> , 2013 , 19, 968-78	5.6	67
140	Pulmonary manifestations of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 13501-11	5.6	49
139	Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. 2014 , 9, e99293		21
138	Pulmonary manifestations of Crohn's disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 133-41	5.6	31
137	Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1582-97	1.5	176
136	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9675-90	5.6	51
135	The liver in pediatric gastrointestinal disease. 2014 , 59, 288-99		11
134	Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation. 2014 , 93, 645-51		13
133	Methotrexate for induction of remission in ulcerative colitis. 2014 , CD006618		18
132	The role of mucosal healing in the treatment of patients with inflammatory bowel disease. 2014 , 12, 103-17		24
131	Methotrexate for induction of remission in refractory Crohn's disease. 2014 , CD003459		39
130	Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. 2014 , 12, 978-85		93
129	A tale of two diseases: the history of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 341-8	1.5	88

128	Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens. 2014 , 99, 3408-17		37
127	Assessment of histologic disease activity in Crohn's disease: a systematic review. 2014 , 20, 2092-103		30
126	Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease. 2015 , 8, 55-9		17
125	The role of endoscopy in inflammatory bowel disease. 2015 , 16, 689-98		4
124	Methotrexate for maintenance of remission in ulcerative colitis. 2015 , CD007560		23
123	Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches. 2015 , 21, 2194-213		50
122	The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. 2015 , 21, 1587-93		26
121	Optimal management of steroid-dependent ulcerative colitis. 2015 , 8, 293-302		12
120	[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy]. 2015 , 66, 231-6		
119	Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 312-7	1.5	26
118	Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. 2015 , 13, 1760-6		39
117	[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. 2015 , 80, 32-73		4
116	[Recommmendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. 2015 , 38, 24-30		13
115	Treat to target: a proposed new paradigm for the management of Crohn's disease. 2015 , 13, 1042-50.e2		190
114	The role and advances of immunomodulator therapy for inflammatory bowel disease. 2015 , 9, 177-89		22
113	Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. 2016 , 22, 1442-9		50
112	Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease. 2016 , 22, 1887-95		20
111	Multiyear Patterns of Serum Inflammatory Biomarkers and Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis. 2016 , 22, 100-5		11

110	The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn's disease. 2016 , 730-753	
109	Metotrexato no es superior a placebo para inducir remisi3n libre de esteroides, pero induce remisi3n cl3nica libre de esteroides en un mayor n3mero de pacientes con colitis ulcerosa. 2016 , 15, 76-78	
108	Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. 2016 , 10, 915-27	56
107	Methotrexate in Crohn's disease: a new face for an old drug?. 2016 , 10, 1135-1144	3
106	Methotrexate for Inflammatory Bowel Diseases - New Developments. 2016 , 34, 140-6	13
105	Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. 2016 , 7, e181	8
104	Safety profile of methotrexate in inflammatory bowel disease. 2016 , 15, 1427-37	15
103	Systematic review: psychological morbidity in young people with inflammatory bowel disease - risk factors and impacts. 2016 , 44, 3-15	49
102	Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. 2016 , 61, 3236-3245	22
101	Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. 2016 , 61, 865-71	24
100	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. 2016 , 28, 802-6	5
99	Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. 2016 , 22, 224-33	71
98	Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. 2016 , 111, 712-9	126
97	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. 2016 , 65, 1447-55	102
96	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. 2016 , 55, 257-74	35
95	Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. 2017 , 15, 84-104	18
94	Conventional Medical Management of Crohn's Disease: Methotrexate. 2017 , 333-342	0
93	Ulcerative colitis. 2017 , 389, 1756-1770	1146

92	Metotrexato en la enfermedad inflamatoria intestinal pediátrica. 2017 , 16, 127-137	
91	Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis. 2017 , 23, 2180-2188	16
90	Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. 2017 , 33, 82-88	31
89	Histologic scoring indices for evaluation of disease activity in Crohn's disease. 2017 , 7, CD012351	16
88	Clinical pharmacokinetics of methotrexate in oncology. 2017 , 2, 137-147	13
87	Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. 2017 , 112, 1849-1858	22
86	Methotrexate for Refractory Crohn's Disease Compared with Thiopurines: A Retrospective Non-head-to-head Controlled Study. 2017 , 23, 440-447	5
85	Second Korean guidelines for the management of ulcerative colitis. 2017 , 15, 7-37	40
84	[Second Korean Guideline for the Management of Ulcerative Colitis]. 2017 , 69, 1-28	16
83	Reduced Unplanned Care and Disease Activity and Increased Quality of Life After Patient Enrollment in an Inflammatory Bowel Disease Medical Home. 2018 , 16, 1777-1785	28
82	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. 2018 , 63, 2729-2739	6
81	Methotrexate Pneumonitis in Crohn's Disease: A Rare Case Report and Review of Literature. 2018 , 54, 535-536	0
80	Quality of Sleep and Coexistent Psychopathology Have Significant Impact on Fatigue Burden in Patients With Inflammatory Bowel Disease. 2018 , 52, 423-430	21
79	A single-center experience with methotrexate in the treatment of Chinese Crohn's disease patients. 2018 , 19, 753-758	2
78	Methotrexate Pneumonitis in Crohn's Disease: A Rare Case Report and Review of Literature. 2018 , 54, 535-536	1
77	Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience. 2018 , 16, 315-318	7
76	The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease. 2018 , 24, 1380-1388	16
75	Methotrexate for inflammatory bowel disease: time for reconsideration. 2019 , 13, 407-409	2

74	Therapy for Crohn's Disease. 2019 , 150-172		
73	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. 2019 , 64, 1622-1631		6
72	Predictors of Suicidal Ideation Among IBD Outpatients. 2019 , 53, e41-e45		5
71	The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 557-566	1.5	11
70	Is there room for immunomodulators in ulcerative colitis?. 2020 , 20, 379-390		2
69	Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. 2020 , 18, 2510-2517.e5		20
68	Structure-based virtual screening, molecular docking and dynamics studies of natural product and classical inhibitors against human dihydrofolate reductase. 2020 , 9, 1		4
67	Traditional Drugs: Mechanisms of Immunosuppressor and Corticosteroid Therapies for Inflammatory Bowel Diseases. 2020 ,		0
66	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. 2020 , 20, 100271		13
65	Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus. 2020 , 26, 1436-1442		6
64	Peripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease. 2020 , 26, 1890-1900		2
63	Gut microbiota-driven drug metabolism in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020 ,	1.5	14
62	Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. 2021 ,		1
61	Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. 2021 , 21, 111-132		1
60	How to do without steroids in inflammatory bowel disease. 6, 48-57		19
59	Drosophila as a Tool for Investigating the Molecular Genetics of Insecticide Resistance. 1993 , 1-37		4
58	State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators. 2011 , 93-110		2
57	Cyclosporin in Inflammatory Bowel Disease. 1990 , 243-254		1

56	Use of Methotrexate for Refractory Inflammatory Bowel Disease. 1990 , 255-265		1
55	THE ROLE OF THE MUCOSAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL DISEASE. 1992 , 21, 451-502		78
54	IMMUNOSUPPRESSANTS. 1992 , 21, 679-693		10
53	NEW THERAPEUTIC APPROACHES. 1995 , 24, 523-540		14
52	MEDICAL MANAGEMENT OF SPECIFIC CLINICAL PRESENTATIONS. 1995 , 24, 541-558		6
51	PREGNANCY AND NURSING. 1995 , 24, 689-698		8
50	Human immunodeficiency virus infection, the acquired immunodeficiency syndrome, and inflammatory bowel disease. 1996 , 23, 24-8		25
49	Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. 1999 , 28, 341-4		42
48	Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. 1996 , 23, 164-71		31
47	Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. 1998 , 26, 129-35		81
46	Serum leptin in children and young adults with inflammatory bowel disease. 1998 , 26, 500-5		58
45	Practical guidelines for the treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 1149-55	5.6	30
44	Current treatment of ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3204-12	5.6	72
43	Crucial steps in the natural history of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 3790-9	5.6	77
42	Impact of medical therapies on inflammatory bowel disease complication rate. <i>World Journal of Gastroenterology</i> , 2012 , 18, 3823-7	5.6	15
41	When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1139-46	5.6	9
40	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. <i>World Journal of Gastroenterology</i> , 2017 , 23, 6385-6402	5.6	31
39	Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide. 2014 , 5, 113-21		22

- 38 Guidelines for the Management of Ulcerative Colitis. **2012**, 10, 1 9
- 37 Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. **2003**, 495-521 1
- 36 Medical therapy for Crohn's disease. **2003**, 659-680
- 35 Medical management of ulcerative colitis. **2003**, 605-629
- 34 Methotrexat als Therapiestrategie bei chronisch entzündlichen Darmerkrankungen. **2003**, 125-137
- 33 SURGICAL TREATMENT OF PERIANAL CROHN'S DISEASE. **2008**, 1995-2023
- 32 CROHN'S DISEASE: AETIOLOGY, PATHOLOGY, DIAGNOSIS AND MEDICAL TREATMENT. **2008**, 1783-1862
- 31 Usefulness of Methotrexate for Arthritis Concomitant with Ulcerative Colitis after Total Proctocolectomy: A Report of Three Cases. **2009**, 62, 334-339
- 30 THE TREATMENT OF THE CHRONIC INFLAMMATORY DISEASES OF INTESTINE WITH THE USE OF IMMUNOSUPPRESSANT BIOLOGICAL DRUGS. **2009**, 17, 147
- 29 La cicatrisation muqueuse endoscopique est-elle un nouvel objectif thérapeutique dans les MICI?. **2010**, 173-180
- 28 Crohn's Disease. **2010**, 211-231
- 27 Conventional Medical Management of Crohn's Disease: Methotrexate. **2012**, 387-395
- 26 Mucosal Healing in IBD: Does it Matter?. 201-206
- 25 Management of Steroid-Dependent and Steroid-Refractory Ulcerative Colitis. **2014**, 313-320
- 24 Antimetabolite Therapy in Ulcerative Colitis: Azathioprine, 6-Mercaptopurine, and Methotrexate. **2014**, 135-143
- 23 Immunosuppressive Drugs: Do They Have Any Role in the Treatment of IBD?. **1990**, 227-234
- 22 5-ASA Preparations in the Treatment of Inflammatory Bowel Disease. **1990**, 179-211
- 21 Intravenous immunoglobulin in idiopathic inflammatory bowel disease: results of an open-label therapeutic trial. **1991**, 359-376

20	Inflammatory Bowel Disease. 1992 , 397-410		
19	Methotrexate in Rheumatoid Arthritis. 1993 , 241-254		
18	Medikamentöse Therapie des Morbus Crohn. 1993 , 184-210		
17	Immunosuppressive agents in IBD: current status and future prospects. 1994 , 367-373		
16	Therapy of IBD in 1994: a surgeon's perspective. 1994 , 424-432		
15	A gastroenterologist's perspective of the medical management of patients with Crohn's disease and ulcerative colitis. 1994 , 385-423		
14	Medikamentöse Therapie des Morbus Crohn. 1996 , 215-241		
13	Medical Therapy. 1999 , 138-149		1
12	The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review. 2015 , 3-28		
11	Ulcerative Colitis. 1378-1417		
10	Methotrexate Therapy. 2008 , 379-386		
9	State-of-the-art therapy in accordance with guidelines. 73-84		
8	Limitations in assessment of mucosal healing in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2010 , 16, 15-20	5.6	10
7	Medical Therapy for Crohn's Disease. 2022 , 781-798		
6	High Sugar-Sweetened Beverage Consumption is Associated with Increased Healthcare Utilization in Inflammatory Bowel Disease: A Multiyear, Prospective Analysis.. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2022 ,	3.9	1
5	A review of the therapeutic management of Crohn's disease.. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 17562848221078456	4.7	0
4	Favourable tolerability and drug survival of tioguanine versus methotrexate after failure of conventional thiopurines in Crohn's disease.. <i>Journal of Crohn's and Colitis</i> , 2022 ,	1.5	1
3	Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 17562848221085889	4.7	0

2 Promises and Problems with the Use of Methotrexate in the Asthmatic Patient. **1991**, 11, 65-79

1 Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice. **2023**, 635, 122741

○